ClinicalTrials.gg
CompletedNCT01307319Updated Feb 20, 2015Results posted

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

A Phase 3 interventional study of BDP HFA and Placebo nasal aerosol in Seasonal Allergic Rhinitis and SAR, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 45 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2015-02-20.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
715
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.

Enrollment
23rd of 101
715 · median 446
Started
2011
with 6 others
Phase 3
47 of 107
none open now
Registered
75th of 107
by date
Lead sponsor
4 of 107
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 23rd largest by enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2011, is one of 47 in phase 3, and was the 75th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of an investigational nasal aerosol at two doses compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis in children (6-11 years of age).

03

Conditions studied

  • Seasonal Allergic Rhinitis
  • SAR

Keywords

  • Allergies
  • Hayfever
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 6 to 11 years of age, as of the Screening Visit (SV)
  • A documented history of SAR to a relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV).
  • A demonstrated sensitivity to at least one seasonal allergen (tree/grass pollen) known to induce SAR through a standard skin prick test.
  • Other criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of physical findings of nasal pathology, including nasal polyps or other respiratory tract malformations, recent nasal , nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit [SV])
  • History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza,) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.
  • Active asthma requiring treatment with inhaled or systemic and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable
  • Have any conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial
  • Other criteria apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
715 participants (actual)

Study arms

  • Experimental
    BDP HFA 80 mcg/day

    Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.

    Drug: BDP HFA

  • Experimental
    BDP HFA 160 mcg/day

    Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.

    Drug: BDP HFA

  • Placebo comparator
    Placebo nasal aerosol once daily

    Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.

    Drug: Placebo nasal aerosol

Interventions

  • BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.

    Also known as: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) Nasal Aerosol, QNASL®

  • DrugPlacebo nasal aerosol

    Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment

    Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported rTNSS over the 4 days prior to randomization.

    Time frame: Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Day 15

Secondary outcomes

  1. Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment

    Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported iTNSS over the 4 days prior to randomization.

    Time frame: Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Day 15

07

Results

Posted Feb 20, 2015

Participant flow

Participant flow — Overall Study
MilestoneBDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once Daily
Started239242234
Safety population239241234
Itt population238241234
Completed235234227
Not completed487
Withdrew: Adverse event221
Withdrew: Lost to follow-up101
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject012
Withdrew: Other043

Outcome measures

SecondaryChange From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment

Instantaneous TNSS is an evaluation of symptom severity over the last 10 minutes prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported iTNSS over the 4 days prior to randomization.

Time frame:
Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Day 15
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment
units on a scaleBDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once Daily
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Instantaneous Total Nasal Symptom Score (iTNSS) During the Two Weeks of Treatment-1.6 ± 0.13-1.7 ± 0.13-1.0 ± 0.13
Statistical analysis
  • BDP HFA 80 mcg/Day vs Placebo Nasal Aerosol Once Daily · mixed-model for repeated measures (MMRM) · p = <0.001 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.63 · 95% CI -1.0 to -0.3The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 mcg/Day vs Placebo Nasal Aerosol Once Daily · mixed-model for repeated measures (MMRM) · p = <0.001 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.73 · 95% CI -1.1 to -0.4The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
PrimaryChange From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment

Reflective TNSS is an evaluation of symptom severity over the past 12 hours prior to the recording of the score. Participants (with assistance from parents/guardians/caregivers, as needed) assessed and recorded four nasal symptoms (runny nose, nasal congestion, nasal itching, and sneezing) twice daily (AM and PM) using the following scale: * 0 = absent (no sign/symptom present) * 1 = mild (sign/symptom clearly present, but minimal awareness; easily tolerated) * 2 = moderate (definite awareness of sign/symptom that is bothersome but tolerable) * 3 = severe (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The total TNSS scale was 0-12 with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms. Baseline was defined as the average AM and PM subject-reported rTNSS over the 4 days prior to randomization.

Time frame:
Baseline (Day -4 to Day 1 predose), Days 1 (postdose) to Day 15
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment
units on a scaleBDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once Daily
Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment-1.9 ± 0.14-2.0 ± 0.14-1.2 ± 0.14
Statistical analysis
  • BDP HFA 80 mcg/Day vs Placebo Nasal Aerosol Once Daily · mixed-model for repeated measures (MMRM) · p = <0.001 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.71 · 95% CI -1.1 to -0.3The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 mcg/Day vs Placebo Nasal Aerosol Once Daily · mixed-model for repeated measures (MMRM) · p = <0.001 (a priori statistical significance is \<0.05.) · Lsm treatment difference from placebo: -0.76 · 95% CI -1.1 to -0.4The MMRM included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.

Adverse events

Collected over Day 1 to Week 6. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP HFA 80 mcg/Day—0/239 (0%)0/239 (0%)
BDP HFA 160 mcg/Day—0/241 (0%)0/241 (0%)
Placebo Nasal Aerosol Once Daily—0/234 (0%)0/234 (0%)

Baseline characteristics

Safety population: the safety population included all randomized participants who received at least one dose of randomized study medication.

Age, Continuous
Age, Continuous(years)BDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once DailyTotal
Mean8.9 ± 1.739.1 ± 1.629.1 ± 1.659.0 ± 1.67
Sex: Female, Male
Sex: Female, Male(Participants)BDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once DailyTotal
Female105116111332
Male134125123382
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once DailyTotal
White169172164505
Black or African American565552163
Asian24612
Other12101234
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once DailyTotal
Hispanic or Latino405345138
Not Hispanic or Latino199188189576
Body Mass Index
Body Mass Index(kg/m^2)BDP HFA 80 mcg/DayBDP HFA 160 mcg/DayPlacebo Nasal Aerosol Once DailyTotal
Mean19.0 ± 4.1519.4 ± 4.5219.1 ± 4.7219.1 ± 4.46
08

Study locations

45 sites
  • Teva Clinical Study Site
    Oxford, Alabama 36203, United States
  • Teva Clinical Study Site
    Bell, California 90201, United States
  • Teva Clinical Study Site
    Costa Mesa, California 92626, United States
  • Teva Clinical Study Site
    Mission Viejo, California 92691, United States
  • Teva Clinical Study Site
    Orange, California 92868, United States
  • Teva Clinical Study Site
    Paramount, California 90723, United States
  • Teva Clinical Study Site
    San Diego, California 92120, United States
  • Teva Clinical Study Site
    San Diego, California 92123, United States
  • Teva Clinical Study Site
    Stockton, California 95207, United States
  • Teva Clinical Study Site
    Centennial, Colorado 80112, United States
  • Teva Clinical Study Site
    Colorado Springs, Colorado 80907, United States
  • Teva Clinical Study Site
    Gainesville, Georgia 30501, United States
  • Teva Clinical Study Site
    Lawrenceville, Georgia 30046, United States
  • Teva Clinical Study Site
    Savannah, Georgia 31406, United States
  • Teva Clinical Study Site
    Stockbridge, Georgia 30281, United States
  • Teva Clinical Study Site
    Indianapolis, Indiana 43208, United States
  • Teva Clinical Study Site
    Bethesda, Maryland 20814, United States
  • Teva Clinical Study Site
    Minneapolis, Minnesota 55402, United States
  • Teva Clinical Study Site
    Plymouth, Minnesota 55441, United States
  • Teva Clinical Study Site
    Columbia, Missouri 65203, United States
  • Teva Clinical Study Site
    Rolla, Missouri 65401, United States
  • Teva Clinical Study Site
    Warrensburg, Missouri 64093, United States
  • Teva Clinical Study Site
    Bozeman, Montana 597158, United States
  • Teva Clinical Study Site
    Brick, New Jersey 08724, United States
  • Teva Clinical Study Site
    High Point, North Carolina 27262, United States
  • Teva Clinical Study Site
    Oklahoma City, Oklahoma 73102, United States
  • Teva Clinical Study Site
    Portland, Oregon 97213, United States
  • Teva Clinical Study Site
    Blue Bell, Pennsylvania 19422, United States
  • Teva Clinical Study Site
    Collegeville, Pennsylvania 19426, United States
  • Teva Clinical Study Site
    Philadelphia, Pennsylvania 19115, United States
  • Teva Clinical Study Site
    Pittsburgh, Pennsylvania 15241, United States
  • Teva Clinical Study Site
    Charleston, South Carolina 20460, United States
  • Teva Clinical Study Site
    Orangeburg, South Carolina 29119, United States
  • Teva Clinical Study Site
    Austin, Texas 78731, United States
  • Teva Clinical Study Site
    Dallas, Texas 75230, United States
  • Teva Clinical Study Site
    Dallas, Texas 75246, United States
  • Teva Clinical Study Site
    El Paso, Texas 79903, United States
  • Teva Clinical Study Site
    Ft. Worth, Texas 76132, United States
  • Teva Clinical Study Site
    Houston, Texas 77054, United States
  • Teva Clinical Study Site
    Kerrville, Texas 78028, United States
  • Teva Clinical Study Site
    New Braunfels, Texas 78130, United States
  • Teva Clinical Study Site
    San Antonio, Texas 78229, United States
  • Teva Clinical Study Site
    Waco, Texas 76712, United States
  • Teva Clinical Study Site
    Burke, Virginia 22015, United States
  • Teva Clinical Study Site
    Richmond, Virginia 23233, United States
09

References and documents

Publications

  • Storms WW, Segall N, Mansfield LE, Amar NJ, Kelley L, Ding Y, Tantry SK. Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2013 Nov;111(5):408-414.e1. doi: 10.1016/j.anai.2013.07.033. Epub 2013 Aug 28. PubMed 24125150 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 3 years 7 months after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 2, 2011
Start
Mar 2011
Primary completionActual
Jul 2011
CompletionActual
Aug 2011
Results delay requested
Aug 25, 2011
Results first posted
Feb 20, 2015
Last update
Feb 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01307319
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Mar 2011
Primary completion
Jul 2011
Completion
Aug 2011
Results posted
Feb 20, 2015
Last update
Feb 20, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion